OCGN COVAXIN Robust Immune Memory to COVID-19 and Variants

NASDAQ:OCGN   Ocugen, Inc
New Data suggest COVAXIN (BBV152) may provide protection against current and future variants!

data from a Phase 3 trial that included nearly 25,800 participants: 77.8% overall efficacy, 93.4% efficacy against severe illness and 65.2% efficacy against the Delta variant.

52 Week Range 0.28 - 18.77

My price target is the 10.30usd resistance.


The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.